SCYNEXIS Inc.

SCYX | NASDAQ

Price Alert Chart Builder DCF Calculator

$4.80

+$0.40 (+9.09%)

Sep 22, 2026, 2:00 PM ET · Market open

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

+9.09%

(1D)

Rating

Updated: Aug 15, 2026

Fundamentals Average

Market Sentiment Bullish

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $30.19M

1D Range

4.36 4.94

52W Range

3.53 9.12

Valuation (TTM)

PE -2.40

PB 0.41

EV/EBITDA 2.39

Valuation (NTM)

Forward PE 1.21

Forward PEG 0.12

Price Target $33

Cash Flow

FCF Yield -48.1%

SBC Adj. FCF Yield -56.6%

SBC Impact -17.7%

Margins

Gross Margin 100.0%

Operating Margin -117.6%

FCF Margin -69.3%

Growth (CAGR)

Revenue 3Y | 5Y -47.9% | 9.8%

Dil EPS 3Y | 5Y 56.2% | 35.3%

FCF 3Y | 5Y -9.8% | 29.6%

Returns

ROA -13.7%

ROE -21.1%

ROIC -32.4%

Financial Health

Net Cash

$52.14M

Current Ratio 9.65

Interest Coverage 0.00

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

SCYNEXIS, Inc. is a biotechnology company, which engages in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several fungal infections, including vulvovaginal...

Sector Healthcare

Industry Medical - Pharmaceuticals

Employees 18

IPO Date May 1, 2014

Website www.scynexis.com

Fiscal Year January - December

Full Company Profile

Latest News

No news articles available yet.

Earnings

Next Earnings

Nov 4, 2026

EPS Est

Pro

Rev Est

Pro

Earnings Details ➞

Analyst Summary

# of Analysts

Consensus

Buy

Price Target

$33

Upside

+587.50%

Buy (1)

Hold (0)

Sell (0)

Analyst Details ➞